NCT07542925 Prediction of Postoperative ICU Requirement in Oncologic Surgery
| NCT ID | NCT07542925 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital |
| Condition | Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-12-15 |
| Primary Completion | 2026-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-12-15 with a primary completion date of 2026-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational cohort study aims to compare the performance of commonly used perioperative risk scoring systems in predicting postoperative intensive care unit (ICU) requirement among adult patients undergoing oncologic surgery. Accurate prediction of postoperative ICU admission is essential for optimizing patient safety and efficient allocation of limited critical care resources, particularly in high-risk oncologic surgical populations. A total of 500 adult patients scheduled for elective or emergency oncologic surgery will be prospectively enrolled at a single tertiary oncology center. Preoperative clinical and demographic data, intraoperative variables, and perioperative characteristics will be recorded using a standardized data collection form. Risk assessment will include the American Society of Anesthesiologists (ASA) Physical Status classification, Surgical Outcome Risk Tool (SORT), Age-adjusted Charlson Comorbidity Index (CACI), Portsmouth Physiological and Operative Severity Score for the enumeration of Mortality and morbidity (P-POSSUM), Eastern Cooperative Oncology Group (ECOG) performance status, Nutritional Risk Screening 2002 (NRS-2002), and preoperative serum albumin levels. The primary outcome is the need for postoperative ICU admission within the first 24 hours after surgery. Secondary outcomes include unplanned ICU admission, duration of ICU stay, need for mechanical ventilation, hospital length of stay, and 30-day mortality. The predictive performance of each scoring system will be evaluated using receiver operating characteristic (ROC) analysis and multivariable logistic regression models.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years and older. * Patients scheduled for elective or emergency oncologic surgery. * Patients who are able to provide written informed consent. * Patients whose data will be analyzed for both planned and unplanned intensive care unit (ICU) admissions. Exclusion Criteria: * Patients under 18 years of age. * Patients requiring continuous ICU follow-up due to a pre-existing critical illness prior to the current surgery. * Patients who do not provide consent to participate in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07542925 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07542925 currently recruiting?
Yes, NCT07542925 is actively recruiting participants. Contact the research team at buslu.1995@gmail.com for enrollment information.
Where is the NCT07542925 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07542925 clinical trial?
NCT07542925 is sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. The trial plans to enroll 500 participants.